If you're researching SAINT™ TMS in Phoenix, you've probably already tried antidepressant medications and psychotherapy. You may have even completed a 6-week course of traditional TMS and not gotten the response you hoped for. You're seeking better, more effective alternatives, and SAINT TMS came across your radar as something to look into.
At the time of writing, Magnus Medical's verified provider directory does not list a SAINT-licensed clinic anywhere in Arizona. The closest verified SAINT providers are in Southern California. What Phoenix does have is a tier of clinics offering accelerated TMS protocols modeled on the Stanford SAINT research (same five-day structure, same iTBS dosage) but without the fMRI-guided targeting that defines the original protocol.
That distinction matters more than most clinic websites will tell you. This article walks through your local options, what licensed SAINT actually costs, why the targeting method is the single most important variable in your decision, and the off-label alternative that we offer at our clinic in Provo, Utah for a fraction of the cost.
At Cognitive FX, we offer accelerated fMRI-guided TMS for patients with treatment-resistant depression at $9,000 to $12,000, with the same five-day structure, theta burst dosage, and personalized fMRI targeting. Book a free consultation to see if it's a good fit.
About this comparison: SAINT™ is a trademark of Stanford University, exclusively licensed to Magnus Medical. Cognitive FX is not affiliated with, endorsed by, or licensed to provide SAINT, and does not use Magnus Medical equipment. We offer fMRI-guided intermittent theta burst TMS, with target locations determined by fMRI and our prescribing physician. We reference SAINT here only to compare treatment options.
Before reading the list below, one quick clarification. "SAINT" refers to two related but distinct things:
Currently, no Phoenix-area clinic appears on Magnus's verified provider list. What Phoenix has is a group of clinics offering off-label accelerated TMS protocols modeled on the SAINT research. The targeting precision (explained below) behind the original protocol is not currently offered by any local Phoenix provider.
Here's what's available locally, plus the closest verified SAINT provider patients in Phoenix realistically consider.
The most established accelerated TMS provider in the Phoenix metro and one of the first centers in the Southwest to offer accelerated TMS, beginning in March 2022. The clinic has treated patients from across the United States and Canada.
The practice offers standard TMS for major depressive disorder and obsessive-compulsive disorder (covered by most insurance providers), as well as accelerated TMS protocols for generalized anxiety disorder, panic disorder, OCD, ADD/ADHD, insomnia, and other off-label conditions.
The accelerated protocol mirrors the SAINT trial schedule: 50 treatments in 5 days, 10 daily sessions of 10 minutes each, with 50-minute breaks between sessions. The clinic uses the MagVenture TMS device, the same device used in the Stanford SAINT clinical studies. Targeting is standard scalp-based or device-protocol placement; fMRI-guided personalized targeting is not part of the offering.
Reported outcomes: 75–85% of patients show at least 50% improvement, with some achieving full remission within 2–6 weeks of completing treatment.
A multi-location practice across the Phoenix metro with an integrated psychiatry-plus-therapy model. Bella Vida offers accelerated TMS alongside ketamine and Spravato treatments, medication management, EMDR, and trauma-focused therapy, making it a good fit for patients looking for an integrated mental health care model rather than a standalone TMS clinic.
The accelerated TMS protocol delivers multiple sessions per day over 5–10 days, modeled on the SAINT research. The clinic explicitly notes the protocol is offered off-label rather than as an FDA-cleared standard protocol. Targeting methodology is not specified in public materials.
A private-pay practice serving Mesa, Gilbert, Chandler, and Tempe, with telehealth consultations available for patients outside the immediate area. The Grove is one of the only private-pay practices in Arizona offering TMS with the Magstim Horizon 3.0 system. The private-pay model is intentional: by stepping outside the insurance approval process, the clinic can offer accelerated protocols that complete care in 1–2 weeks instead of the traditional 6.
Targeting is done with the Magstim Horizon neuronavigation rather than fMRI-guided functional connectivity targeting. The clinic treats depression, anxiety disorders, and OCD.
A multi-location practice positioning around what they call "TMS Therapy with Brain Scan Technology", which includes FDA-approved TMS combined with EEG-based brain mapping to create a personalized care plan.
Worth knowing for readers comparing options: EEG-based brain mapping is a different modality from the resting-state fMRI functional connectivity targeting used in the SAINT protocol. EEG measures electrical activity at the scalp surface; fMRI measures functional connectivity between areas of the brain. These approaches are not equivalent for the purpose of identifying the personalized DLPFC target that defines SAINT. The next section explains why this matters.
The clinic treats major depressive disorder, OCD, anxiety, PTSD, and other mental health conditions, with reported outcomes of 50–60% significant improvement and 30–40% remission in treatment-resistant patients.
Offers accelerated TMS as an alternative to the traditional TMS schedule, administering multiple sessions per day to provide a condensed timeline. Specific protocol details (sessions per day, total treatment days, targeting method) are not publicly detailed on the clinic's site.
Mayo Clinic's Department of Psychiatry and Psychology in Scottsdale offers standard transcranial magnetic stimulation through its psychiatric services and is often the first major academic medical center Phoenix patients consider. Based on public materials at the time of writing, Mayo does not currently position itself as a SAINT-licensed provider or as an accelerated SAINT-modeled clinic, and the TMS offering follows the standard 6-week TMS protocol covered by most insurance providers.
If you specifically want the licensed Magnus SAINT system rather than an off-label equivalent, BrainHealth Solutions in Costa Mesa, CA, is the geographically closest verified SAINT provider to Phoenix. The clinic also has locations in Westwood (Los Angeles) and Jurupa Valley.
The full SAINT protocol delivers 1,800 pulses of iTBS hourly, 10 times a day, for 5 days, using a resting-state functional connectivity MRI to specify the treatment target. The clinic reports a response rate of 93% and a remission rate of 66% at 5 days after treatment. Beyond SAINT, they offer standard rTMS (covered by most insurance), OCD-specific TMS, and psychiatric second-opinion consultations.
All Phoenix-area accelerated TMS providers operate as private practices. Mayo Clinic is the academic exception, but it offers only the traditional rTMS protocol. Standard 6-week TMS therapy is covered by most major insurance providers throughout Arizona. Any form of accelerated TMS is essentially never covered and is offered on a self-pay basis.
The Medicare and Medicaid hospital outpatient exception for licensed SAINT (which provides a CMS reimbursement rate of $19,703 for hospitals delivering the protocol) doesn't apply to any Phoenix-area provider, since they're all private practices. At verified SAINT providers in California and elsewhere, out-of-pocket pricing ranges from $30,000 to $36,000 for the full one-week course.
The meaningful variation across Phoenix clinics is targeting methodology, ranging from manual scalp-based measurements to EEG-guided. None currently offer fMRI-guided functional connectivity targeting. The next section explains why that variable matters more than any other in determining outcomes.
For the most current licensing status, you can check Magnus Medical's verified provider directory directly before committing to any clinic.
Wait times at verified SAINT clinics are commonly several weeks. Phoenix's off-label accelerated TMS providers typically have more scheduling availability. Before committing, ask each clinic:
Clinical studies on SAINT TMS are strong, but the high price keeps it out of reach for most patients who need it.
Commercial insurance providers do not currently cover SAINT. The exception is Medicare and Medicaid patients receiving SAINT in hospital outpatient settings under the new CMS payment rate. None of the verified SAINT providers within driving distance of Arizona qualify under this rule, so for Phoenix patients seeking SAINT, the cost is out of pocket.
Among verified SAINT clinics that publicly share pricing, the out-of-pocket cost for the one-week program ranges from $30,000 to $36,000. For most Phoenix households, that's the equivalent of several months of rent or mortgage. Even patients with substantial HSA or FSA savings often find it difficult to fully cover the cost pre-tax.
Both SAINT and accelerated fMRI-guided TMS qualify as eligible medical expenses for HSA and FSA accounts, and most clinics will issue superbills with CPT codes that support out-of-network insurance claims and medical expense deductions. It’s worth asking any clinic about this before committing, as the difference between clinics that handle documentation well and clinics that don't can be thousands of dollars in reimbursement.
The practical question is whether an equivalent protocol exists at a lower price.
The five-day schedule and the accelerated pulse pattern are reproducible across any provider with the right equipment. What actually varies meaningfully between accelerated TMS providers, and what drives the difference in outcomes, is how the treatment target is identified.
For a Phoenix reader without local SAINT access, the targeting question is the most consequential variable in choosing where to go.
Patients receiving fMRI-guided targeting were 2.3× more likely to respond than those receiving the same protocol without it.
TMS works by stimulating a specific region of the dorsolateral prefrontal cortex (DLPFC). In patients with depression, this region shows reduced functional connectivity with deeper structures involved in mood regulation. The therapeutic effect of TMS depends on activating the right spot.
The DLPFC isn't a single point. It spans several centimeters across the surface of the brain, and the exact spot most strongly connected to a given patient's depression circuit varies meaningfully from person to person. Hitting that spot is the difference between modulating the depression circuit or not.
This is why traditional TMS (which does not use precise fMRI targeting) achieves remission in only about 30% of treatment-resistant patients. The protocol is consistent, but where the magnetic pulses actually land varies. For patients whose depression circuit happens to sit in an unusual location, standard targeting can miss the mark by enough to undermine treatment.
The same TMS protocol can produce very different outcomes depending on how the target is found.
As targeting precision increases, so do response and remission rates. Patients receiving fMRI-guided TMS were 2.3× more likely to respond than those receiving the same protocol without it.
A recent real-world analysis compared outcomes between patients receiving fMRI-guided accelerated TMS and patients receiving the same accelerated protocol without fMRI guidance. Same five-day schedule. Same stimulation dosage. The only difference was the targeting method.
The same analysis found that patients receiving fMRI-guided accelerated TMS were 2.3 times more likely to respond than those receiving the same protocol without it. In the original Stanford SAINT trial, 85.7% of patients responded, and 78.6% achieved remission after five days of fMRI-guided iTBS—substantially higher than the ~33% remission rate typically seen with standard rTMS in pivotal FDA studies. (Individual results vary.)
This isn't a small effect. Targeting precision is the single variable that most consistently separates strong accelerated TMS outcomes from average ones.
See why the difference between a population average and your exact brain coordinate can determine whether treatment works
Standard TMS protocols use a single coordinate derived from population averages. That coordinate may be centimeters away from the specific spot in your prefrontal cortex that connects to your depression circuit. When the target is off, the magnetic pulse stimulates tissue that isn’t driving your depression — and treatment fails, not because TMS doesn’t work, but because it didn’t treat your brain.
This is likely the most common reason people try TMS and feel like it “didn’t work.” The technology worked. The address was wrong.
Look at the dots on the brain above. The spread between the population-average targets and any custom coordinate you place represents real anatomical variance — variance that determines treatment outcome.
Before your first pulse, Cognitive FX runs a resting-state fMRI scan. That scan maps the connectivity between your prefrontal cortex and the subgenual cingulate — the specific circuit that drives depression. We find the exact voxel in your DLPFC with the strongest connection to that circuit. That voxel becomes your treatment coordinate.
No other clinic in Utah does this. Most TMS providers pick a coordinate from a chart and apply the same protocol to every patient. We treat the brain in front of us.
Use the panel on the left to enter approximate coordinates and see where your target might fall — or schedule a consultation and we’ll find your exact location with imaging.
A meaningful share of patients searching for SAINT have already completed a course of standard 6-week TMS locally and didn't get the response they hoped for. The natural conclusion is "TMS doesn't work for me." The more accurate framing is often "TMS didn't work at that target location for me."
If a patient's depression circuit sits in a less typical part of the DLPFC, scalp-based targeting can effectively send the magnetic pulses to the wrong address. The treatment was delivered to brain tissue that isn't part of the patient's depression circuit, and the lack of response reflects targeting error rather than treatment failure.
Previous TMS failure isn't a contraindication to fMRI-guided accelerated TMS. For many patients, it's the strongest indicator that targeting precision is what was missing the first time.
The accelerated TMS clinics in Phoenix deliver the SAINT schedule and dosage, which is real value over traditional TMS. What they don't currently deliver is the targeting precision that drove the SAINT trial's remission rates. For treatment-resistant patients specifically, the population for whom SAINT was developed, targeting precision matters most precisely because their depression has already failed multiple treatment options, and a near-miss target may be part of why.
SAINT integrates the three elements that drove the Stanford trial outcomes:
The schedule and the iTBS pulse pattern are reproducible by any provider with the right equipment, and Phoenix accelerated TMS clinics already reproduce them.
The piece that's harder to reproduce is the fMRI-guided targeting itself. Not because the equipment is unavailable; clinical-grade resting-state fMRI is available at most academic medical centers and an increasing number of specialty clinics. The harder part is the clinical expertise required to analyze that fMRI data and identify the precise functional connectivity target.
Magnus Medical's licensed system automates this analysis with FDA-cleared proprietary software. However, a trained clinical neuroscientist with fMRI experience can identify the same target by manually analyzing the same data. The question is whether the provider already has that expertise in-house.
This is where Cognitive FX becomes a viable alternative. We've been performing clinical fMRI scans for more than 25 years as part of our broader brain rehabilitation program. The targeting capability isn't a new addition for TMS; it's a core clinical skill our neuroscientists and physicians have been developing since long before SAINT existed.
At Cognitive FX, we deliver accelerated fMRI-guided intermittent theta burst TMS, with targeting determined by fMRI and our prescribing physician, for $7,000-$12,000.
| Cognitive FX fMRI-Guided TMS | Magnus SAINT™ TMS | |
|---|---|---|
| FDA-approved iTBS | Yes | Yes |
| FDA-approved neuronavigation | Yes | Yes |
| FDA-approved figure-8 coils | Yes | Yes |
| Treatment days | 5 | 5 |
| Sessions per day | 10 | 10 |
| Total sessions | 50 | 50 |
| Total TMS pulses | ~90,000 | 90,000 |
| Motor threshold pulse intensity | 90–120% | 90–120% |
| Personalized DLPFC targeting | fMRI analysis + personalized E-field coil orientation assists doctor in target location | FDA-approved proprietary software |
| CBT included | Yes | Varies by provider |
| Cost | $7,000–$12,000 | $30,000+ |
We use in-house fMRI analysis instead of Magnus's proprietary software. Magnus licenses an FDA-cleared algorithm that identifies the spot in the DLPFC most functionally anti-correlated with the subgenual cingulate. Our prescribing neuroscientist and physician analyze the same connectivity patterns from your fMRI data and identify the same target. The methodology may be different, but the end result is the same precision targeting of your individualized DLPFC coordinate.
It's similar to the difference between a brand-name medication and a compounded version: same active mechanism, same clinical intent, without the licensing cost. Because we don't pay Magnus's licensing fees, we can offer thetreatment for $9,000 to $12,000 instead of $30,000+.
We use E-field modeling for coil orientation. Magnus's current SAINT protocol places the coil based on the scalp coordinate above your target. We go a step further: an E-field model accounts for how your individual brain anatomy bends the magnetic field, and we orient the coil to deliver dosage accurately to your target voxel. This is a meaningful refinement that improves dose precision.
CBT is integrated during your treatment week. Cognitive behavioral therapy combined with brain stimulation improves response rates by ~8% and remission rates by ~19% compared to TMS alone. We include CBT sessions during the five-day treatment week, plus resources to continue CBT after you return home. Most SAINT-licensed clinics are psychiatry-only operations and don't include this.
fMRI-guided accelerated TMS, 5-day course
The exact sequence of sessions, rest periods, and CBT varies by patient. The rhythm above illustrates the general pattern: short bursts of stimulation alternating with rest and therapy throughout the day. No anesthesia or sedation is involved.
About this comparison: SAINT™ is a trademark of Stanford University, exclusively licensed to Magnus Medical. Cognitive FX is not affiliated with, endorsed by, or licensed to provide SAINT, and does not use Magnus Medical equipment. We offer fMRI-guided intermittent theta burst TMS, with target locations determined by fMRI and our prescribing physician. We reference SAINT here only to compare treatment options.
There's something else worth knowing about Cognitive FX that doesn't show up in protocol comparisons. We're not a standalone TMS clinic. We're a brain rehabilitation clinic that has treated post-concussion syndrome, long COVID, and other neurological conditions for over a decade, and TMS therapy sits inside that broader clinical context.
For treatment-resistant depression patients whose symptoms have a neurological contributor, this matters clinically. The Southwest sees its share of motorcycle accidents, ATV injuries, and other concussion sources that often go undiagnosed for years. Many patients with severe depression have a history of head injury or post-viral illness they don't think of as significant: a car accident a decade ago, sports concussions in college, lingering symptoms after a 2021 COVID infection.
Our fNCI brain scan can identify whether something other than pure psychiatric depression is driving symptoms. This information sometimes changes the treatment direction entirely. No Phoenix-area accelerated TMS clinic offers this evaluation, because no Phoenix-area accelerated TMS clinic is operating inside a broader brain injury treatment program.
Disclaimer: SAINT™ is a trademark of The Board of Trustees of the Leland Stanford Junior University ("Stanford") and has been exclusively licensed to Magnus Medical. Cognitive FX is neither endorsed by Stanford nor utilizes Magnus Medical equipment, nor do we claim to offer the SAINT™ protocol as prescribed by Stanford or Magnus Medical. We provide fMRI-guided intermittent theta burst TMS with target locations determined by fMRI and our prescribing physician.
Accelerated TMS isn't always a one-and-done treatment, and most clinic marketing won't tell you that clearly. Honest patient guidance has to include what comes after the treatment week because the post-treatment plan matters as much as the treatment itself.
The Stanford SAINT trial showed strong initial remission rates of about 78%, but those rates degraded over follow-up to roughly 60% maintained remission at four weeks. Longer-term durability data is still emerging. Some patients sustain remission for many months or longer. Others benefit from a booster course at 6–12 months. A smaller subset don't respond durably and need to consider other treatment options.
At Cognitive FX, our post-treatment care includes:
A practical reality worth naming: Phoenix has a deep mental health care market. The therapy and psychiatry infrastructure that maintains your results over the long term is in your home city, regardless of where you do TMS. Our approach assumes this. The treatment week is the first intervention; the maintenance is local. We don't try to replace your existing care team; we work alongside them.
Our accelerated TMS program is not appropriate for:
If you're over 65 and you've been searching for SAINT or accelerated TMS, you'll be better served by the standard 6-week TMS protocol available at most Phoenix clinics, including Mayo Clinic. The 6-week protocol is well-studied in older adults, covered by Medicare and most insurance providers, and produces meaningful response rates.
If you're set on receiving SAINT TMS (or an equivalent fMRI-guided protocol), there’s a need to consider travel costs in addition to the cost of treatment.
You have the California-based clinics, charging $30,000+ for the official 5-day SAINT protocol (excluding travel). And you also have the option of our $9,000 to $12,000 off-label SAINT equivalent in Provo, Utah.
Both options are five-day, out-of-pocket protocols. The meaningful difference for most Phoenix patients is somewhere between $18,000 and $26,000 in total cost.
Phoenix to Salt Lake City is one of the easier domestic routes in the country. Direct flights operate from PHX on Delta, Southwest, American, and JetBlue, with flight time around 1 hour 45 minutes. If you fly into Salt Lake City International, the drive to our clinic in Provo takes roughly 45 minutes. Provo Municipal Airport (PVU) is 10–15 minutes from the clinic and is served by Allegiant on select routes.
We have accommodation partnerships near the clinic with patient rates and shuttle service to and from treatment each day of the five-day program. You'll get text messages and check-in support from our team throughout the week, so the logistics of being out of state don't add to your cognitive load during treatment.
| Cognitive FX (PHX patient) |
Magnus SAINT (CA verified provider) |
|
|---|---|---|
| Round-trip flight | $150–$400 | $150–$400 |
| Five nights accommodation | $750–$1,500 | $1,000–$2,500 (LA rates) |
| Treatment | $9,000–$12,000 | $30,000–$36,000 |
| Total all-in | $10,000–$14,000 | $31,000–$39,000 |
Even accounting for travel and lodging in both scenarios, Cognitive FX comes out roughly a third of the cost of licensed SAINT.
There's no single right answer here. The best option depends on your situation.
At the time of writing, licensed Magnus SAINT isn't available at any clinic in the Phoenix metro or elsewhere in Arizona. The closest verified SAINT providers are in California, where pricing typically ranges from $30,000 to $36,000 for the full one-week course. Phoenix accelerated TMS clinics offering off-label SAINT-modeled protocols generally don't disclose pricing publicly; expect to learn it during a consultation.
No commercial insurance providers currently cover SAINT. The only exception is Medicare and Medicaid patients receiving SAINT in a hospital outpatient setting under the CMS reimbursement rate of $19,703. No Phoenix-area providers qualify under this rule. Standard 6-week TMS for major depressive disorder and OCD is widely covered by insurance providers across Arizona.
Yes. Both SAINT and accelerated fMRI-guided TMS qualify as eligible medical expenses for HSA and FSA accounts. Because our treatment is roughly a third of the cost of SAINT, the same HSA balance covers a substantially larger share of the total.
We provide superbills with CPT codes, itemized receipts, and treatment summary letters that support medical expense deductions, HSA/FSA reimbursement, and out-of-network insurance claims. Documentation requirements vary by plan, so we recommend checking with your insurance provider about what they need before treatment.
SAINT is a specific licensed product from Magnus Medical that uses FDA-cleared proprietary software to analyze fMRI data and identify a personalized DLPFC target. Non-licensed providers offering fMRI-guided accelerated TMS use the same fMRI scan type, the same iTBS delivery, and the same five-day schedule, but rely on a trained clinical neuroscientist to analyze the imaging data and select the target manually. The treatment a patient receives is functionally equivalent.
Generally, no. Most Phoenix clinics positioning around SAINT are offering off-label accelerated TMS protocols modeled on the SAINT research (same five-day schedule, same iTBS dosage) without the fMRI-guided functional connectivity targeting that defines the licensed SAINT system. Always ask directly what targeting method the clinic uses.
No. MRI-based device neuronavigation uses a structural MRI to place the coil over the anatomical DLPFC. fMRI-guided targeting uses functional MRI to identify which part of the DLPFC is functionally connected to your specific depression circuit. Both are improvements over scalp-based targeting, but they're not equivalent. Functional connectivity targeting is what drives the higher response and remission rates in the SAINT clinical studies.
No. SAINT™ specifically refers to a protocol which uses Magnus Medical’s proprietary targeting software. However, our fMRI-guided theta burst TMS follows the same number of sessions, total pulse count, iTBS delivery, fMRI targeting, FDA-approved equipment at $9,000 to $12,000 instead of $30,000+.
Most licensed SAINT clinics have multi-week waitlists due to capacity. Off-label accelerated TMS providers in Phoenix typically have more scheduling availability. Ask each clinic directly about their current wait time.
This is one of the most common reasons patients come to us. Standard TMS using scalp-based targeting can miss the spot in your prefrontal cortex actually driving your depression by up to 2 cm. When the target is off, treatment fails not because TMS doesn't work, but because it lacks precision. Personalized fMRI targeting addresses this directly. The recent naturalistic study showed patients receiving fMRI-guided accelerated TMS were 2.3x more likely to respond than patients receiving the same protocol without fMRI guidance.
Yes. Some patients sustain remission for many months after treatment without further intervention. Others benefit from a booster course at 6–12 months if symptoms return. Our follow-up protocol includes guidance on what to watch for and when a booster makes sense, with coordination back to your local psychiatry team in Phoenix.
Our TMS program is currently focused on major depressive disorder and treatment-resistant depression. We don't treat OCD, anxiety disorders, bipolar disorder, or other mental health conditions with TMS at this time. Our broader brain rehabilitation program treats post-concussion syndrome, long COVID and other viral brain injuries, POTS, and lingering symptoms after stroke or TIA, and for some patients with treatment-resistant depression, those underlying neurological factors are part of what's driving symptoms.
TMS hasminimal side effects. The most common are mild headache and temporary scalp discomfort at the treatment site, typically resolving quickly. TMS is non-invasive, drug-free, and requires no sedation or downtime between sessions.
If you've been weighing SAINT in Phoenix and the cost or local availability is the barrier, talk to us first. Our free 30-minute consultation is a telehealth call with a member of our clinical team. You can also take our short quiz to see if you're a good fit for treatment, or call us directly at 385-446-4161.
Dr. Mark D. Allen holds a Ph.D. in Cognitive Science from Johns Hopkins University and received post-doctoral training in Cognitive Neuroscience and Functional Neuroimaging at the University of Washington. As a co-founder of Cognitive Fx, he played a pivotal role in establishing the unique and exceptional treatment approach. Dr. Allen is renowned for his pioneering work in adapting fMRI for clinical use. His contributions encompass neuroimaging biomarkers development for post-concussion diagnosis and innovative research into the pathophysiology of chronic post-concussion symptoms. He's conducted over 10,000 individualized fMRI patient assessments and crafted a high-intensity interval training program for neuronal and cerebrovascular recovery. Dr. Allen has also co-engineered a machine learning-based neuroanatomical discovery tool and advanced fMRI analysis techniques, ensuring more reliable analysis for concussion patients.
Transcranial magnetic stimulation (TMS) has been FDA-approved for treating major depressive disorder (MDD) since 2008 and is a well-established treatment option, especially for patients who haven’t...
Access to SAINT™ TMS in the U.S. remains extremely limited, with fewer than ten clinics currently offering the protocol. On top of that, the cost often exceeding $30,000 and has limited insurance...
For many people living with major depression, antidepressant medications either don’t work or only get them part of the way to recovery. Symptoms may ease for a while, but then return, or never fully...
If you’re considering transcranial magnetic stimulation (TMS) therapy, you may be concerned about its side effects and whether the benefits outweigh any risks.
Many patients who consider or undergo transcranial magnetic stimulation (TMS therapy) want to understand how this treatment affects their brains.
Traditional antidepressant medications involve a trial period of weeks or months before it can be determined whether or not they are working. If a medication doesn’t work — and it’s been shown that ...
